Theravance Inc. (THRX) and GlaxoSmithKline (GSK) announced late Wednesday afternoon that the Pulmonary-Allergy Drugs Advisory Committee of the FDA voted that the efficacy and safety data provide substantial evidence to support approval of BREO ELLIPTA.
Theravance has gapped open sharply higher Thursday and is now up 4.41 at $32.42. The stock has broken out to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
December 19, 2025 15:10 ET U.S. inflation data and interest rate decisions by major central banks were the highlights of this busy week for economics news flow. Employment data and survey results on the housing markets also gained attention in the U.S. In Europe, the European Central Bank and Bank of England announced their policy decisions and macroeconomic projections.